Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Sep 6, 2026, 8:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–17 of 17 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Intervention: OGT918 Clear all

Conditions: Pompe Disease (Late-onset)
Interventions: AT2221, ATB200; Drug · Biological
Lead sponsor: Amicus Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 18
States / cities: Little Rock, Arkansas • Irvine, California • Gainesville, Florida + 14 more

Conditions: Pompe Disease
Interventions: Rituximab, Miglustat; Drug
Lead sponsor: University of Florida; Other
Eligibility: Up to 65 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2017
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Pompe Disease
Interventions: Cipaglucosidase alfa, Miglustat, Alglucosidase alfa or Avalglucosidase alfa, Untreated; Biological · Drug · Other
Lead sponsor: Amicus Therapeutics; Industry
Eligibility: Not listed
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2034
U.S. locations: 15
States / cities: Little Rock, Arkansas • Irvine, California • Jacksonville, Florida + 10 more

Conditions: Contraception
Interventions: Miglustat (Zavesca); Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Pompe Disease (Late-onset)
Interventions: Cipaglucosidase Alfa, Miglustat, Alglucosidase Alfa, Placebo; Biological · Drug
Lead sponsor: Amicus Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 25
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Irvine, California + 21 more

Conditions: Batten Disease
Interventions: Miglustat 100 milligrams (mg) Oral Capsule; Drug
Lead sponsor: Beyond Batten Disease Foundation; Other
Eligibility: 17 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Gaucher Disease
Interventions: OGT 918; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 4 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: GM1 Gangliosidoses, GM2 Gangliosidoses, Tay-Sachs Disease, Sandhoff Disease
Interventions: miglustat, Ketogenic Diet; Drug · Other
Lead sponsor: University of Minnesota; Other
Eligibility: Up to 204 Months
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Pompe Disease Infantile-Onset
Interventions: ATB200, AT2221; Biological · Drug
Lead sponsor: Amicus Therapeutics; Industry
Eligibility: 0 Years to 17 Years
U.S. locations: 2
States / cities: Oakland, California • Gainesville, Florida

Conditions: HIV Infections
Interventions: Butyldeoxynojirimycin, Zidovudine; Drug
Lead sponsor: G D Searle; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 9
States / cities: San Francisco, California • Tarzana, California • Miami Beach, Florida + 6 more

Conditions: Niemann Pick Diseases
Interventions: OGT918; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 12 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 2
States / cities: Bethesda, Maryland • New York, New York

Conditions: HIV Infections
Interventions: Butyldeoxynojirimycin; Drug
Lead sponsor: G D Searle; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 6
States / cities: San Diego, California • Stanford, California • Miami, Florida + 3 more

Conditions: GM2 Gangliosidoses, Tay-Sachs, Sandhoff Disease
Interventions: Zavesca (Miglustat); Drug
Lead sponsor: Children's National Research Institute; Other
Eligibility: 6 Months to 5 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Pompe Disease (Late-onset)
Interventions: Cipaglucosidase Alfa, Miglustat; Biological · Drug
Lead sponsor: Amicus Therapeutics; Industry
Eligibility: 0 Years to 17 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 9
States / cities: Gainesville, Florida • Jacksonville, Florida • Atlanta, Georgia + 6 more

Conditions: Glycogen Storage Disease Type II Infantile Onset
Interventions: Cipaglucosidase alfa, Miglustat; Biological · Drug
Lead sponsor: Amicus Therapeutics; Industry
Eligibility: Up to 17 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 6
States / cities: Gainesville, Florida • Atlanta, Georgia • Durham, North Carolina + 3 more

Conditions: HIV Infections
Interventions: Butyldeoxynojirimycin, Zidovudine; Drug
Lead sponsor: G D Searle; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 6
States / cities: Miami, Florida • Chicago, Illinois • Indianapolis, Indiana + 3 more

Conditions: Pompe Disease
Interventions: ATB200, AT2221; Drug
Lead sponsor: Amicus Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 12
States / cities: Phoenix, Arizona • Orange, California • Gainesville, Florida + 9 more

Search by objective public record fields.

A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD)

Observational Study for Subjects With Pompe Disease Undergoing Immune Modulation Therapies

A Global Prospective Observational Registry of Patients With Pompe Disease

Glycosphingolipid Inhibition and Spermatogenesis in Man: A Pilot Study (MIG 2)

A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe Disease

An Open-label Safety, Pharmacokinetic, and Efficacy Study of Miglustat for the Treatment of Subjects With Batten Ceroid Lipofuscinosis, Neuronal 3 (CLN3) Disease

OGT 918-006: A Phase I/II Randomized, Controlled Study of OGT 918 in Patients With Neuronopathic Gaucher Disease

Synergistic Enteral Regimen for Treatment of the Gangliosidoses

Expanded Access for ATB200/AT2221 for the Treatment of IOPD

Phase II Study of the Safety and Surrogate Marker Efficacy of Butyldeoxynojirimycin (SC-48334) and AZT in Symptomatic HIV-1 Infected Patients With 200 - 500 CD4+ Cells/mm3. (NOTE: Asymptomatic HIV-1 Infected Patients Also Eligible)

Saccadic Eye Movements in Patients With Niemann-Pick Type C Disease

Phase I Rising Dose Tolerability Study of SC-48334 in Patients With Acquired Immunodeficiency Syndrome (AIDS) and Advanced AIDS Related Complex

Pharmacokinetics, Safety and Tolerability of Zavesca (Miglustat) in Patients With Infantile Onset Gangliosidosis: Single and Steady State Oral Doses

ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD

A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18

Initial Phase II Efficacy and Safety Study of SC-48334 Administered in Combination With Low-Dose Zidovudine (AZT) to Symptomatic HIV-1 Infected Patients With = or > 200 to = or < 500 CD4+ Cells/mm3

First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221